Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease
Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.Posted: April 2006
Related articles
- Genzyme Provides Update on U.S. Marketing Application for Myozyme - January 17, 2006
- Genzyme Submits BLA for Myozyme for Treatment of Pompe Disease - July 29, 2005
Myozyme (alglucosidase alfa) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
